Patients with refractory metastatic colorectal cancer experience survival benefits with fruquintinib

Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that the targeted therapy fruquintinib significantly improved overall survival (OS) and progression-free survival (PFS) in patients with refractory metastatic colorectal cancer. Findings from the global FRESCO-2 trial, published today in The Lancet, were first presented at the European Society for Medical Oncology (ESMO) Congress 2022.

Related Keywords

Australia ,Texas ,United States ,Japan ,China ,American ,Arvind Dasari ,American Cancer Society ,University Of Texas Md Anderson Cancer Center ,European Society For Medical Oncology ,European Union ,Drug Administration ,Cancer Center ,European Society ,Medical Oncology ,Gastrointestinal Medical ,